Biogen Inc. and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared

Biogen vs. BioCryst: A Decade of SG&A Spending Trends

__timestampBioCryst Pharmaceuticals, Inc.Biogen Inc.
Wednesday, January 1, 201474610002232342000
Thursday, January 1, 2015130470002113100000
Friday, January 1, 2016112530001947900000
Sunday, January 1, 2017139330001935500000
Monday, January 1, 2018295140002106300000
Tuesday, January 1, 2019371210002374700000
Wednesday, January 1, 2020679290002504500000
Friday, January 1, 20211188180002674300000
Saturday, January 1, 20221593710002403600000
Sunday, January 1, 20232138940002549700000
Monday, January 1, 20242403700000
Loading chart...

In pursuit of knowledge

SG&A Spending Patterns: Biogen Inc. vs. BioCryst Pharmaceuticals, Inc.

In the competitive landscape of biotechnology, understanding the financial strategies of industry leaders is crucial. Over the past decade, Biogen Inc. and BioCryst Pharmaceuticals, Inc. have demonstrated contrasting approaches to their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Biogen's SG&A expenses have consistently been over 30 times higher than those of BioCryst, reflecting its expansive operational scale. Notably, Biogen's spending peaked in 2021, reaching nearly 2.7 billion dollars, while BioCryst's expenses have shown a remarkable growth trajectory, increasing by over 2,700% from 2014 to 2023. This surge highlights BioCryst's aggressive expansion and investment in administrative capabilities. As the biotech sector continues to evolve, these spending patterns offer valuable insights into the strategic priorities and growth potential of these two influential companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025